Past Trainees


Monica Akre, PhD

Monica AkreMy work focusses on the use of cell line expression data and corresponding drug responsiveness with the goal of identifying predictive expression profiles that will better direct use of effective therapeutics and avoid ineffective options.

Taylor Harding, PhD

Taylor HardingUsing pre-clinical modeling to identify transcriptomic signatures that accurately predict drug resistance in multiple myeloma. Additionally, we are testing new chemotherapeutic approaches to target unique features of the myeloma epigenome and improve the efficacy of current therapies.

Gregory Laffen, PharmD

Gregory LaffenPharmacogenomic determinants of the serum uric acid lowering effects of the drug fenofibrate. We aim to determine if there are genetic markers that can be used as predictors of both drug response and serum uric acid levels that can be used to help guide clinical decision making in order to improve treatment of gout and help ease the burden of comorbid cardiovascular disease.

Malek Okour, PhD

Malek OkourPharmacokinetics and pharmacodynamics analysis of mycophenolic acid (MPA) in kidney transplant recipients. We aim into individualizing therapy while keeping in mind exposure relation to acute rejection and side effects.

Rebecca Pulk, PharmD

Rebecca PulkTacrolimus is a calcineurin inhibitor immunosuppressant that widely used in kidney transplant. I am working to improve our ability to select an optimized tacrolimus dose for kidney transplant patients based on their individual clinical and genetic factors to decrease time to optimal coverage and improve clinical outcomes.

Youssef Roman, PharmD, PhD

youssef romanThe contribution of genetic polymorphisms in select genes responsible for uric acid disposition and the drugs used to treat hyperuricemia and gout. My ultimate goal is to identify key genetic variants to be used for guided drug selection to optimally manage patients with gout, hyperuricemia, and their associated comorbidities.

Kinjal Sanghavi, PhD

Kinjal SanghaviImproving immunosuppressive therapy in transplantation using population pharmacokinetic and pharmacogenetic approach. These approaches were used to optimize dosing for tacrolimus (for kidney transplant recipients) and fludarabine (for hematopoietic stem cell transplant recipients).

Stephan Seibert

Stephan SeibertTacrolimus is the cornerstone immunosuppressive agent after kidney transplantation, but its high pharmacokinetic variability is a well-known problem which contributes to adverse effects and poor outcomes. We are investigating the associations between intra-patient tacrolimus pharmacokinetic variability, CYP3A5 loss of function alleles, and acute rejection in a large cohort of African American and European American kidney transplant recipients.